

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Technology Appraisal**

**Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis (ID6732)**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Aiforia Technologies Plc</li> <li>• AIRA Matrix Private Ltd</li> <li>• Ibex Medical Analytics</li> <li>• Mindpeak GmbH</li> <li>• Prima</li> <li>• Tempus (Paige)</li> <li>• Visiopharm A/S</li> </ul> <p><u>Patient and carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Breast Cancer Now</li> <li>• Cancer Black Care</li> <li>• CoppaFeel!</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Lobular Breast Cancer UK</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Make 2nds Count</li> <li>• Marie Curie</li> <li>• MET UP UK</li> <li>• National Hereditary Breast Cancer Helpline</li> <li>• Pink Ribbon Foundation</li> <li>• Prevent Breast Cancer</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• The Inflammatory Breast Cancer Network UK</li> <li>• UK Charity for Triple Negative Breast Cancer</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Association of British Healthcare Industries</li> <li>• Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)</li> <li>• Board of Community Health Councils in Wales</li> <li>• British Healthcare Trades Association</li> <li>• British In Vitro Diagnostics Association (BIVDA)</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• HealthTech Alliance</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Screening Committee</li> <li>• NHS Breast Screening Programme</li> <li>• NHS Confederation</li> <li>• NHS Supply Chain</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• National Pathology Imaging Cooperative (NPIC)</li> <li>• United Kingdom Accreditation Service (UKAS)</li> <li>• Welsh Cancer Network</li> <li>• Welsh Government</li> </ul> <p><u>Other relevant companies</u></p> <ul style="list-style-type: none"> <li>• FujiFilm</li> </ul>

Provisional stakeholder list for the evaluation of Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis (ID6732)

Issue date: May 2026

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Breast Pathology</li> <li>• Association of Breast Surgery</li> <li>• Association of Cancer Physicians</li> <li>• Association for Clinical Biochemistry and Laboratory Medicine</li> <li>• Association of Clinical Pathologists</li> <li>• Association of Palliative Care Medicine of Great Britain</li> <li>• British Association of Plastic Reconstructive and Aesthetic Surgeons</li> <li>• British Division of the International Academy of Pathology</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Lymphology Society</li> <li>• British Medical Association</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> <li>• Digital Pathology Association</li> <li>• Institute of Biomedical Science</li> <li>• Northern Ireland Cancer Network</li> <li>• Nursing and Midwifery Council</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Physicians and Surgeons of Glasgow</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons of Edinburgh</li> <li>• Royal College of Surgeons of England</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• The Association for Cancer Surgery</li> <li>• UK Breast Cancer Group</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Digital</li> </ul>	<ul style="list-style-type: none"> <li>• House Medical Consultants Ltd</li> <li>• Indica Labs</li> <li>• Leica Biosystems</li> <li>• Philips</li> <li>• Roche</li> <li>• SAH Diagnostics</li> <li>• Sectra Ltd</li> <li>• Siemens</li> <li>• Sysmex</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Breast Cancer Hope</li> <li>• Cochrane Breast Cancer Group</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Institute for Health Research</li> <li>• Pro Cancer Research Fund</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul> <p><u>Evidence review group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme (NETSCC)</li> </ul> <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> <li>• NICE - National Guideline Alliance (cancer, mental health, and women and children's health)</li> <li>• Scottish Intercollegiate Guidelines Network</li> <li>• Health Technology Wales</li> </ul>

Provisional stakeholder list for the evaluation of Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis (ID6732)

Issue date: May 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.